시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 주의력결핍 과잉행동장애(ADHD) 시장 보고서(2025년)
Attention Deficit Hyperactivity Disorder Global Market Report 2025
상품코드 : 1720719
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,342,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,167,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,992,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

주의력결핍 과잉행동장애(ADHD) 시장 규모는 향후 수년간 강력한 성장이 예상될 예정입니다. 예측 기간의 성장은 정신 건강 문제의 수용 확대, 어린이 식사에 있어서의 첨가물·보존료의 사용 증가 등이 견인한다고 보여집니다. 이 기간의 주요 동향으로서는 기술의 향상과 혁신적인 치료법, 진단·치료법의 진보, 새로운 치료제의 개발, 비자극성약에의 시프트, 약물 치료의 진보 등을 들 수 있습니다.

맞춤형 의료의 채용 확대는 향후 몇 년간의 주의력결핍 과잉행동장애(ADHD) 시장의 성장을 견인할 것으로 예측됩니다. 이 접근법은 개인의 특성에 대응한 커스터마이즈된 치료 전략을 가능하게 함으로써 ADHD의 관리를 대폭 강화하여 보다 적은 효과적인 개입으로 이어집니다. 예를 들어, 2024년 2월 개인 맞춤형 의약품 연합의 보고서에 따르면 개인 맞춤형 의약품이 2023년 FDA 신약 승인 건수의 3분의 1 이상을 차지하며 4년 연속 증가세를 이어갔습니다.

주의력결핍 과잉행동장애(ADHD) 시장의 각 회사는 효과를 향상시키고, 환자의 규정 준수를 강화하고, 증상을 장기간 억제하기 위해 서방형 정제와 같은 혁신적인 치료법의 개발에 주력하고 있습니다. 이러한 정제는 약물을 서서히 방출하기 때문에 1회 복용으로 하루 종일 일관된 증상을 조절할 수 있습니다. 이것은 여러 번 복용의 필요성을 줄이고 ADHD 환자의 편의성과 치료 계획 준수를 향상시킵니다. 예를 들어 캐나다에 본사를 두고 있는 제약회사 JAMP Pharma Group은 2022년 2월 다케다 캐나다사의 INTUNIV XR의 제네릭 의약품인 Guanfacine XR을 출시했습니다. Guanfacine XR은 뇌의 수용체를 표적으로 삼아 주의력, 충동 조절, 다동성을 개선하는 장시간 작용제입니다. 다양한 강도(1mg, 2mg, 3mg, 4mg)가 있어 100정이므로 유연한 치료가 가능합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental condition marked by persistent inattention, hyperactivity, and impulsivity that disrupt daily functioning. It typically starts in childhood and may continue into adulthood, affecting focus, self-control, and organizational skills. Treatment options include behavioral therapy, medication, and lifestyle changes.

The primary types of ADHD treatment are stimulants and non-stimulants. Stimulants are medications that increase brain activity to improve focus, attention, and impulse control, and are commonly used for managing ADHD. ADHD treatments are categorized by age (children and adults) and gender (male and female). ADHD medications come in various forms, including tablets, capsules, and others, and are distributed through multiple channels such as retail pharmacies, hospital pharmacies, and online pharmacies.

The attention deficit hyperactivity disorder market research report is one of a series of new reports from The Business Research Company that provides attention deficit hyperactivity disorder market statistics, including the attention deficit hyperactivity disorder industry global market size, regional shares, competitors with the attention deficit hyperactivity disorder market share, detailed attention deficit hyperactivity disorder market segments, market trends, and opportunities, and any further data you may need to thrive in the attention deficit hyperactivity disorder industry. This attention deficit hyperactivity disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The attention deficit hyperactivity disorder market size has grown strongly in recent years. It will grow from $16.29 billion in 2024 to $17.43 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period can be attributed to the rising prevalence of ADHD, the increasing incidence of ADHD in children, growing awareness of the condition, higher healthcare expenditure, and government initiatives focused on mental health awareness.

The attention deficit hyperactivity disorder market size is expected to see strong growth in the next few years. It will grow to $22.59 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period is expected to be driven by an increasing number of pediatric and adult patients receiving treatment, enhanced healthcare infrastructure, a growing adoption of personalized medicine, greater acceptance of mental health issues, and the rising use of additives and preservatives in children's diets. Key trends during this period include improvements in technology and innovative treatments, advancements in diagnostic and treatment methods, the development of new therapeutic agents, a shift towards non-stimulant medications, and progress in pharmaceutical treatments.

The increasing adoption of personalized medicine is expected to drive the growth of the attention deficit hyperactivity disorder (ADHD) market in the coming years. Personalized medicine is a healthcare approach that customizes treatments based on an individual's genetic, environmental, and lifestyle factors, leading to more precise and effective therapies. The growing interest in personalized medicine can be attributed to advancements in genomic technologies, which allow treatments to be tailored to a person's genetic profile. This approach significantly enhances the management of ADHD by enabling customized treatment strategies that address an individual's unique characteristics, leading to more targeted and effective interventions. For example, in February 2024, a report from the Personalized Medicine Coalition revealed that personalized medicines accounted for over a third of new FDA drug approvals in 2023, marking the fourth consecutive year. The FDA approved 16 new personalized treatments for rare diseases, 7 cancer drugs, and 3 other treatments. As a result, the growing adoption of personalized medicine is driving the expansion of the ADHD market.

Companies in the ADHD market are focusing on developing innovative treatments such as extended-release tablets to improve efficacy, enhance patient compliance, and provide long-lasting symptom control. These tablets release medication gradually, providing consistent control of symptoms throughout the day with a single dose. This reduces the need for multiple doses, improving convenience and adherence to the treatment plan for individuals with ADHD. For instance, in February 2022, JAMP Pharma Group, a pharmaceutical company based in Canada, launched Guanfacine XR, a generic version of Takeda Canada Inc.'s INTUNIV XR. Guanfacine XR is a long-acting medication that targets receptors in the brain to improve attention, impulse control, and hyperactivity. Available in various strengths (1 mg, 2 mg, 3 mg, and 4 mg) and packaged in 100-count bottles, the drug offers flexibility in treatment.

In September 2024, Collegium Pharmaceutical Inc., a US-based specialty pharmaceutical company, acquired Ironshore Therapeutics Inc. for $525 million. This acquisition is part of Collegium's strategy to expand its portfolio beyond pain management and strengthen its presence in the growing ADHD market, particularly with its differentiated ADHD product, Jornay PM. Ironshore Therapeutics, also based in the US, focuses on developing and commercializing therapies for ADHD.

Major players in the attention deficit hyperactivity disorder market are Pfizer Inc., Johnson & Johnson, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Supernus Pharmaceuticals Inc., Neos Therapeutics Inc., Collegium Pharmaceutical Inc., Mallinckrodt Pharmaceuticals plc, Tris Pharma Inc., Arbor Pharmaceuticals LLC, Akili Interactive Labs Inc., Mind Medicine (MindMed) Inc., NeuroSigma Inc., KemPharm Inc., RespireRx Pharmaceuticals Inc., Cingulate Therapeutics LLC, and Adlon Therapeutics L.P.

North America was the largest region in the attention deficit hyperactivity disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in attention deficit hyperactivity disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the attention deficit hyperactivity disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The attention deficit hyperactivity disorder market consists of revenues earned by entities by providing services such as diagnosis, therapy, counselling, medication management, and digital health solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The attention deficit hyperactivity disorder (ADHD) market also includes sales of medical devices, digital therapeutics, and assistive learning tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Attention Deficit Hyperactivity Disorder Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on attention deficit hyperactivity disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for attention deficit hyperactivity disorder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The attention deficit hyperactivity disorder market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Attention Deficit Hyperactivity Disorder Market Characteristics

3. Attention Deficit Hyperactivity Disorder Market Trends And Strategies

4. Attention Deficit Hyperactivity Disorder Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Attention Deficit Hyperactivity Disorder Growth Analysis And Strategic Analysis Framework

6. Attention Deficit Hyperactivity Disorder Market Segmentation

7. Attention Deficit Hyperactivity Disorder Market Regional And Country Analysis

8. Asia-Pacific Attention Deficit Hyperactivity Disorder Market

9. China Attention Deficit Hyperactivity Disorder Market

10. India Attention Deficit Hyperactivity Disorder Market

11. Japan Attention Deficit Hyperactivity Disorder Market

12. Australia Attention Deficit Hyperactivity Disorder Market

13. Indonesia Attention Deficit Hyperactivity Disorder Market

14. South Korea Attention Deficit Hyperactivity Disorder Market

15. Western Europe Attention Deficit Hyperactivity Disorder Market

16. UK Attention Deficit Hyperactivity Disorder Market

17. Germany Attention Deficit Hyperactivity Disorder Market

18. France Attention Deficit Hyperactivity Disorder Market

19. Italy Attention Deficit Hyperactivity Disorder Market

20. Spain Attention Deficit Hyperactivity Disorder Market

21. Eastern Europe Attention Deficit Hyperactivity Disorder Market

22. Russia Attention Deficit Hyperactivity Disorder Market

23. North America Attention Deficit Hyperactivity Disorder Market

24. USA Attention Deficit Hyperactivity Disorder Market

25. Canada Attention Deficit Hyperactivity Disorder Market

26. South America Attention Deficit Hyperactivity Disorder Market

27. Brazil Attention Deficit Hyperactivity Disorder Market

28. Middle East Attention Deficit Hyperactivity Disorder Market

29. Africa Attention Deficit Hyperactivity Disorder Market

30. Attention Deficit Hyperactivity Disorder Market Competitive Landscape And Company Profiles

31. Attention Deficit Hyperactivity Disorder Market Other Major And Innovative Companies

32. Global Attention Deficit Hyperactivity Disorder Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Attention Deficit Hyperactivity Disorder Market

34. Recent Developments In The Attention Deficit Hyperactivity Disorder Market

35. Attention Deficit Hyperactivity Disorder Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기